Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical (ISRG) reported its quarterly earnings results late today, amassing a profit that gained more than 18% year-over-year.
The post Intuitive Surgical Earnings: ISRG Stock Down Despite Q2 Profit Beat appeared first on InvestorPlace.

Intuitive Surgical Earnings: ISRG Stock Down Despite Q2 Profit Beat

Intuitive Surgical stock attempted a breakout Friday after the robotic surgery giant topped second-quarter earnings and sales estimates, though it saw a moderation in hernia procedures.
The post How One Key Metric Could Tug On Intuitive Surgical's Attempted Breakout appeared first on Investor's Business Daily.

How One Key Metric Could Tug On Intuitive Surgical's Attempted Breakout

More hospitals are using this new method to get systems in-house.

This Key Trend Continues at Intuitive Surgical

Robotic surgical system manufacturer Intuitive Surgical, Inc. (NASDAQ: ISRG) reported above-consensus second-quarter results Thursday.

Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts

Intuitive Surgical (ISRG) expects 2019 procedure growth within 16-17%.

Intuitive Surgical (ISRG) Q2 Earnings Beat, Guidance Narrowed

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q2 2019 Results - Earnings Call Transcript

Intuitive Surgical earnings of $3.25 per share beat estimates as $1.1 billion in sales also topped. But Intuitive Surgical stock slipped late Thursday.

Robotic Surgery Giant Crushes Earnings Forecasts, But Stock Dips

Boston Scientific

Penumbra

Neuronetics Inc

Stryker

Along with issues around ongoing talcum and opioid exposure, some rivals may have been winning at the company’s expense.

5 Medtech Companies May Be Winning at Johnson & Johnson’s Expense

JNJ earnings report could be a boon for medical stocks Boston Scientific and Penumbra, an analyst said Wednesday. Boston has efforts in electrophysiology.

These 4 Medical Stocks Could Benefit From J&J Earnings — Here's Why

Intuitive Surgical's (ISRG) acquisition of Scholly Fiberoptic's robotic endoscope business to likely boost the acquirer's da Vinci Surgical system.

Intuitive Surgical to Boost da Vinci Platform With Buyout

Amazon

Sirius XM Holdings Inc

Margins for these top growth stocks should significantly improve over time.

3 Brand-Name Growth Stocks That Keep Getting Better With Age

Intuitive Surgical (ISRG) closed the most recent trading day at $526.25, moving -1.82% from the previous trading session.

Intuitive Surgical (ISRG) Stock Sinks As Market Gains: What You Should Know

Abbott Labs

Illumina

Johnson & Johnson

These healthcare stocks are breaking down on the charts. Investors should be careful before stepping into these four.

4 Healthcare Stocks That Are Feeling Sick  

Intuitive Surgical (ISRG) expects its core Instruments and Accessories unit to boost second-quarter 2019 results.

Can Instruments Drive Intuitive Surgical (ISRG) Q2 Earnings?

Cerner

Medtronic

The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.

Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD

Intuitive Surgical (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intuitive Surgical (ISRG) Earnings Expected to Grow: Should You Buy?

Intuitive Surgical (NASDAQ:ISRG) manufactures and sells robotic surgical systems. Its primary device is the da Vinci Surgical System, which helps surgeons perform minimally invasive surgeries through directions from a console.

How Much Can Intuitive Surgical's System Revenue Grow Over The Next Three Years?

NextEra Energy

AT&T

Visa

These diverse growth and income stocks will help you claim financial freedom.

5 Top Stocks to Secure Your Financial  Independence

We summarize Intuitive Surgical’s ethos and its product line and assess its business model.

A Premium Company At A Premium Price With A Few Tricks Up Its Sleeve

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Celgene

Cigna

CVS Health

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

5 Health Care Stocks in Gurus’ Portfolios

Anthem

FireEye

General Electric

Home Depot

STAG Industrial

Intuitive Surgical, Home Depot and Anthem are just some of the top stocks to buy when interest rates stop edging higher.

7 Stocks to Buy for a Dovish Fed

Mettler-Toledo

ServiceNow

White Mountains Insurance Group

Forget low-priced stocks. The best stocks to buy could be the high-priced ones.

5 High-Price Stocks to Buy Worthy of Your Portfolio

Iovance Biotherapeutics

These three healthcare stocks could be outstanding additions to your portfolio.

Three Top Healthcare Stocks to Buy Right Now

Aurora Cannabis

Cardiovascular Systems

Haemonetics

QuidelOrtho Corp

Medical Products Industry Outlook: Growth Prospects Radiant

Brookfield Infrastructure Partners L.P.

Alphabet

Three very different stocks in very different industries. But they're all great picks for cautious investors.

News for Intuitive Surgical Stock (ISRG)